Becton Dickinson & Co. stock BDX, -0.55% slid 1.3% in premarket trade Thursday, after the medical tech and diagnostics company beat estimates for its fiscal fourth quarter but offered guidance that lagged. The Franklin Lakes, N.J.-based company posted net income of $265 million, or 92 cents a share, for the quarter to Sept. 30, up from $242 million, or 84 cents a share, in the year-earlier period. Adjusted per-share earnings came to $2.
75, a penny ahead of the FactSet consensus. Revenue fell 1.8% to $4.761 billion from $4.849 billion, also ahead of the $4.710 billion FactSet consensus. The company now expects fiscal 2023 revenue of about $18.6 billion to $18.8 billion, below the FactSet consensus of $19.3 billion. It expects adjusted EPS of $11.85 to $12.10, below the $12.19 FactSet consensus. Shares have fallen 11% in the year to date, while the S&P 500 SPX, -2.08% has fallen 21%.
My guess is they looked good and well.